All MRK Content

Merck & Co., Inc. (MRK) New Survey Shows HPV Awareness Isn’t Keeping Pace with Certain HPV-Related Cancer Trends in Canada

Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release

April 15, 20261 min read

Merck & Co., Inc. (MRK) Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release

April 13, 20261 min read

Merck & Co., Inc. (MRK) Goldman Sachs 45th Annual Global Healthcare Conference

Merck & Co., Inc. (NYSE: MRK) FY 2024 Corporate Conference

April 13, 20261 min read

Merck & Co., Inc. (MRK) Acquisition of Cidara Therapeutics By Merck

Merck & Co., Inc. (NYSE: MRK) FY 2025 Special/M&A Conference

April 9, 20261 min read

Merck & Co., Inc. (MRK) Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

Merck & Co., Inc. (NYSE: MRK) FY 2026 M&A Release

April 7, 20261 min read

Merck & Co., Inc. (MRK) Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration

Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release

April 2, 20261 min read

Merck & Co., Inc. (MRK) European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens

Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release

April 2, 20261 min read

Merck & Co., Inc. (MRK) Q1 2026 Earnings Call

Merck & Co., Inc. (NYSE: MRK) Q1 2026 Earnings Conference

April 1, 20261 min read

Merck & Co., Inc. (MRK) Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release

March 30, 20261 min read

Merck & Co., Inc. (MRK) Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release

March 29, 20261 min read